top of page

Skyhawk's novel RNA-targeting small molecule for Huntington's Disease, SKY-0515, is in clinical trials. A second Skyhawk-developed drug candidate, SKY-1214, for Multiple Myeloma and Non-Hodgkins Lymphoma is progressing through IND-enabling studies  

SKYHAWK invents novel small molecules that modify RNA expression, targeting some of the world's most intractable diseases.

Our unique platform accelerates building RNA targeting small molecules across a range of fields including neurology, oncology and fibrosis.

We have built collaborations with BMS, Biogen, Genentech, Ipsen, Merck, Sanofi, Takeda and Vertex that leverage our novel SKYSTAR® platform to
target challenging diseases in a variety of therapeutic areas. 

Small Molecules that Modify RNA Expression

Latest News

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

today announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and the appointment of Bill Haney, former Chief Executive Officer and Co-founder of Skyhawk Therapeutics, to Executive Chairman of the Board of Directors.

Growing the
Pipeline for Patients

We have entered the clinic with, SKY-0515, targeting Huntington's Disease, and plan to file INDs for four additional drug candidates targeting high unmet need indications across neurology and oncology.

tet for Robin.png
MAPT E10 for Robin.png
HTT Image for Robin.png

Skyhawk’s platform has generated an expanding internal pipeline of neurology, oncology and fibrosis assets

DNA helix structure hologram, genetic concept..jpg

Our Platform


Proprietary Platform

Skyhawk’s platform integrates four distinct and complementary technologies with rapid growing, machine learning models to accelerate the development of RNA targeting small molecule drugs across a range of targets.


Our Collaborations

Skyhawk’s seven Pharma partnerships sparked rapid investment in our proprietary platform.

Skyhawk’s Pharma collaborations have contributed biology insights, commercial perspectives and upfront payments of over $525 million to develop targeted drug candidates – driving growth in Skyhawk’s platform. 

bottom of page